Core A is organized to meet demonstrated statistical needs of participating scientists in the areas of biostatistical design and analysis, and data management. Please see the Appendix for additional descriptions of biostatistical methodology. The objectives of Core A are as follows: 1. To assist in the biostatistical design of clinical and laboratory studies in this Program Project Grant (PPG). 2. To assist in the analysis of research data. In this role, the core provides assistance to multiple investigators in implementing study protocol design, data entry, data monitoring and analysis and manuscript w r i t i n g . 3. To provide experienced staff to carry out analyses. 4. To assist investigators in all aspects of data management including the organization of their data flow and in the choice and setup of data base management systems. 5. To develop biostatistical methodology for statistical problems arising in this PPG. 6: To provide scientific input more generally as a member of the Executive Committee.

Public Health Relevance

Core A will support all three projects and work closely with other Cores, especially with respect to analyzing data from the trial in combination with the archival patient material. To develop further support for Projects I, II and III we have been pursuing various statistical methodologies for the handling of incomplete data.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
John Wayne Cancer Institute
Santa Monica
United States
Zip Code
Wang, Jinhua; Huang, Sharon K; Marzese, Diego M et al. (2015) Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol 135:532-41
Lessard, Laurent; Liu, Michelle; Marzese, Diego M et al. (2015) The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching. J Invest Dermatol 135:2464-74
Wang, Jinhua; Hua, Wei; Huang, Sharon K et al. (2015) RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb. Oncotarget 6:30165-77
Deutsch, Gary B; Kirchoff, Daniel D; Faries, Mark B (2015) Metastasectomy for stage IV melanoma. Surg Oncol Clin N Am 24:279-98
Faries, Mark B (2015) From the guest editor: The sentinel node: evolution of the revolution. Introduction. Cancer J 21:1-2
Marzese, Diego M; Hoon, Dave Sb (2015) Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn 15:647-64
Faries, M B; Cochran, A J; Elashoff, R M et al. (2015) Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of t Br J Dermatol 172:571-3
Marzese, Diego M; Liu, Michelle; Huynh, Jamie L et al. (2015) Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res 28:82-93
Ono, Shigeshi; Oyama, Takashi; Lam, Stella et al. (2015) A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget 6:7053-64
Cochran, Alistair J; Huang, Rong-Rong; Su, Albert et al. (2015) Is sentinel node susceptibility to metastases related to nodal immune modulation? Cancer J 21:39-46

Showing the most recent 10 out of 248 publications